🇺🇸 FDA

Company profile · Sponsor

Medicenna

Medicenna Therapeutics

MDNAF · NYSE pharma TORONTO, A6, USA
Pipeline
3
Drugs
0
Patents
8

Quick answer

Medicenna (MDNAF) is a pharma company. headquartered in TORONTO, A6, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker MDNAF
Exchange NYSE
Company type pharma
Headquarters TORONTO, A6, USA
SEC CIK 0001807983

Pipeline (3)

Search pipeline →

  1. KEYTRUDA 25 mg/mL concentrate for solution for infusion, MDNA11

    Medicenna

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  2. MDNA11

    Medicenna

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  3. MDNA55

    Medicenna

    Glioblastoma

    phase 2 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12404497

    Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12338269

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12274735

    IL-4-fusion formulations for treatment of central nervous system (CNS) tumors

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11680090

    Interleukin-2 fusion proteins and uses thereof

    Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11542312

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11352402

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10781242

    Interleukin-2 fusion proteins and uses thereof

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10106592

    Interleukin-4 receptor-binding fusion proteins and uses thereof

    Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Medicenna?

Medicenna (MDNAF) is a pharma company. headquartered in TORONTO, A6, USA. listed on NYSE. NovaPharmaNews links 3 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Medicenna sponsor?

We track 3 ClinicalTrials.gov-linked programs for Medicenna, including KEYTRUDA 25 mg/mL concentrate for solution for infusion, MDNA11 and 2 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Medicenna company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.